Marcadia Biotech lands $15M in venture funding

Carmel drug developer Marcadia Biotech has received a $15 million venture capital investment from Frazier Healthcare Ventures of Seattle and locally based Twilight Venture Partners.

The funding will help Marcadia develop projects including a glucagon analog for emergency treatment of hypoglycemia, the company announced today.

Marcadia, which is led by former senior executives of Eli Lilly and Co. and Guidant Corp., is developing technology licensed from Indiana University Research and Technology Corp.

Please enable JavaScript to view this content.

Story Continues Below

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our updated comment policy that will govern how comments are moderated.

{{ articles_remaining }}
Free {{ article_text }} Remaining
{{ articles_remaining }}
Free {{ article_text }} Remaining Article limit resets on
{{ count_down }}